Bristol Myers Squibb (BMY) Asset Writedowns and Impairment (2010 - 2026)

Bristol Myers Squibb (BMY) has 17 years of Asset Writedowns and Impairment data on file, last reported at $412.0 million in Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at $412.0 million, up 8140.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 49.28% YoY), and the FY2025 annual result was $1.1 billion, down 62.94% from the prior year.
• Asset Writedowns and Impairment fell to $412.0 million in Q1 2026 per BMY's latest filing, from $584.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $2.0 billion in Q4 2024 and troughed at $1.0 million in Q1 2024.
• A 5-year average of $288.6 million and a median of $61.0 million in 2022 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2024 and 2026: Asset Writedowns and Impairment sank 95.0% in 2024, then soared 8140.0% in 2026.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $35.0 million in 2022, then slipped by 17.14% to $29.0 million in 2023, then soared by 6634.48% to $2.0 billion in 2024, then slumped by 70.1% to $584.0 million in 2025, then decreased by 29.45% to $412.0 million in 2026.
• Business Quant data shows BMY's Asset Writedowns and Impairment at $412.0 million in Q1 2026, $584.0 million in Q4 2025, and $196.0 million in Q3 2025.